Lawrie TA, Nordin A, Chakrabarti M. Medical and surgical treatments for usual-type vulvar intraepithelial neoplasia. JAMA Oncol. 2016;2(12):1647–8. https://doi.org/10.1001/jamaoncol.2016.2430.
Adams TS, Rogers LJ, Cuello MA. Cancer of the vagina: 2021 update. Int J Gynaecol Obstet. 2021;155 Suppl 1(Suppl 1):19–27. https://doi.org/10.1002/ijgo.13867.
•• Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52(5):611–22. https://doi.org/10.1097/QAI.0b013e3181b327ca. One of the most important meta-analysis on Non AIDS cancers' incidence in PLWH.
Article PubMed PubMed Central Google Scholar
Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–47. https://doi.org/10.1056/NEJMoa0810097.
Bakker NAM, Rotman J, van Beurden M, Zijlmans HJM, van Ruiten M, Samuels S, et al. HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial. J Immunother Cancer. 2021;9(8). https://doi.org/10.1136/jitc-2021-002547.
Olesen TB, Sand FL, Aalborg GL, Munk C, Kjaer SK. Incidence of penile intraepithelial neoplasia and incidence and survival of penile cancer in Denmark, 1997 to 2018. Cancer Causes Control. 2022;33(1):117–23. https://doi.org/10.1007/s10552-021-01510-5.
Hoekstra RJ, Trip EJ, Ten Kate FJ, Horenblas S, Lock MT. Penile intraepithelial neoplasia: nomenclature, incidence and progression to malignancy in the Netherlands. Int J Urol. 2019;26(3):353–7. https://doi.org/10.1111/iju.13871.
Olesen TB, Sand FL, Rasmussen CL, Albieri V, Toft BG, Norrild B, et al. Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 2019;20(1):145–58. https://doi.org/10.1016/S1470-2045(18)30682-X.
Article CAS PubMed Google Scholar
• Mooij SH, van Santen DK, Geskus RB, van der Sande MA, Coutinho RA, Stolte IG, et al. The effect of HIV infection on anal and penile human papillomavirus incidence and clearance: a cohort study among MSM. AIDS. 2016;30(1):121–32. https://doi.org/10.1097/QAD.0000000000000909. One of the most interesting paper on penile HPV prevalence among MSM with and without HIV.
Kreuter A, Brockmeyer NH, Weissenborn SJ, Gambichler T, Stucker M, Altmeyer P, et al. Penile intraepithelial neoplasia is frequent in HIV-positive men with anal dysplasia. J Invest Dermatol. 2008;128(9):2316–24. https://doi.org/10.1038/jid.2008.72.
Article CAS PubMed Google Scholar
Penile cancer Guidelines. https://uroweb.org/guidelines/penile-cancer . Accessed 04 April 2023.
Burd EM, Dean CL. Human papillomavirus. Microbiol Spectr. 2016;4(4). https://doi.org/10.1128/microbiolspec.DMIH2-0001-2015.
Saunders-Wood T, Egawa N, Zheng K, Giaretta A, Griffin HM, Doorbar J, et al. Role of E6 in maintaining the basal cell reservoir during productive papillomavirus infection. J Virol. 2022;96(5):e0118121. https://doi.org/10.1128/JVI.01181-21.
Broomall EM, Reynolds SM, Jacobson RM. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. Postgrad Med. 2010;122(2):121–9. https://doi.org/10.3810/pgm.2010.03.2129.
•• IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 90. https://monographs.iarc.who.int/wpcontent/uploads/2018/06/mono90.pdf. Accessed 31 January 2023. Essential Document on HPV carcinogenesis.
Winer RL, Gheit T, Cherne S, Lin J, Stern JE, Poljak M, et al. Prevalence and correlates of beta human papillomavirus detection in fingernail samples from mid-adult women. Papillomavirus Res. 2018;5:1–5. https://doi.org/10.1016/j.pvr.2017.11.002.
Edelstein ZR, Schwartz SM, Hawes S, Hughes JP, Feng Q, Stern ME, et al. Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis. 2012;39(11):860–7. https://doi.org/10.1097/OLQ.0b013e318269d098.
Article PubMed PubMed Central Google Scholar
• National Cancer Institute. HPV and cancer. 2023. https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer. Accessed 31 January 2023. An updated source on epidemiology and risk factors for HPV and cancer.
•• Marra E, Lin C, Clifford GM. Type-specific anal human papillomavirus prevalence among men, according to sexual preference and HIV status: a systematic literature review and meta-analysis. J Infect Dis. 2019;219(4):590–8. https://doi.org/10.1093/infdis/jiy556. An excellent manuscript for understanding HPV prevalence in Men living with and without HIV.
Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012;30 Suppl 5(0 5):F24–33. https://doi.org/10.1016/j.vaccine.2012.05.089.
Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110(5):525–41. https://doi.org/10.1042/CS20050369.
Article CAS PubMed Google Scholar
Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24(Suppl 1):S16-22. https://doi.org/10.1016/j.vaccine.2005.09.002.
Article CAS PubMed Google Scholar
Maglennon GA, McIntosh PB, Doorbar J. Immunosuppression facilitates the reactivation of latent papillomavirus infections. J Virol. 2014;88(1):710–6. https://doi.org/10.1128/JVI.02589-13.
Article CAS PubMed PubMed Central Google Scholar
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.
Kuhdari P, Previato S, Giordani M, Biavati P, Ferretti S, Gabutti G, et al. The burden of HPV-related diseases in Italy, 2001–12. J Public Health (Oxf). 2017;39(4):730–7. https://doi.org/10.1093/pubmed/fdx025.
Article CAS PubMed Google Scholar
Ibrahim Khalil A, Mpunga T, Wei F, Baussano I, de Martel C, Bray F, et al. Age-specific burden of cervical cancer associated with HIV: A global analysis with a focus on sub-Saharan Africa. Int J Cancer. 2022;150(5):761–72. https://doi.org/10.1002/ijc.33841.
Article CAS PubMed Google Scholar
• Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021;9(2):e161–9. https://doi.org/10.1016/S2214-109X(20)30459-9. Interesting meta-analysis that includes 24 studies, showing an increased pooled risk of cervical cancer in WLHIV with Africa and Eastern Asia as the most affected regions.
Article CAS PubMed Google Scholar
• Rohner E, Butikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, et al. Cervical cancer risk in women living with HIV across four continents: a multicohort study. Int J Cancer. 2020;146(3):601–9. https://doi.org/10.1002/ijc.32260.Retrospectivemulti-cohortobservationalstudy. Collecting data from all over the world in order to assess global inequities in the burden of invasive cervical cancer among WLHIV.
Article CAS PubMed Google Scholar
• Grover S, Bhatia R, Friebel-Klingner TM, Mathoma A, Vuylsteke P, Khan S, et al. Cervical cancer screening in HIV-endemic countries: An urgent call for guideline change. Cancer Treat Res Commun. 2023;34:100682. https://doi.org/10.1016/j.ctarc.2023.100682. Prospective Multicentric Cohort study from Botswana, supporting WHO guidelines new update which includes younger WLHIV in cervical cancer screening: age of diagnosis for invasive cervical cancer is younger in Countries with high prevalence of HIV infection.
UNAIDS-Botswana. 2021. https://www.unaids.org/en/regionscountries/countries/botswana. Accessed 31 January 2023.
•• Gupta R, Mariano LC, Singh S, Gupta S. Highly active antiretroviral therapy (HAART) and outcome of cervical lesions and high-risk HPV in women living with HIV (WLHIV): A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2022;278:153–8. https://doi.org/10.1016/j.ejogrb.2022.09.031. An important meta-analysis showing cART positive impact on incidence, progression, regression of cervical lesions and acquisition or clearance of HPV infection in WLHIV.
Article CAS PubMed Google Scholar
Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P, Art, et al. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5(1):e45-e58. https://doi.org/10.1016/S2352-3018(17)30149-2.
•• Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018;32(6):795–808. https://doi.org/10.1097/QAD.0000000000001765. A large meta-analysis showing higher risk of hr-HPV infection and precancerous lesions among WLHIV; furthermore, this manuscript focuses on independent risk factors on incidence and prognosis.
WHO. guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2nd ed. WHO Guidelines Approved by the Guidelines Review Committee. Geneva2021. https://www.ncbi.nlm.nih.gov/pubmed/34314129. Accessed 31 January 2023.
Cibula D, Potter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother Oncol. 2018;127(3):404–16. https://doi.org/10.1016/j.radonc.2018.03.003.
• Ntekim A, Campbell O, Rothenbacher D. Optimal management of cervical cancer in HIV-positive patients: a systematic review. Cancer Med. 2015;4(9):1381–93. https://doi.org/10.1002/cam4.485. A systematic review which describes current available evidence regarding cervical cancer clinical management ant treatment among WLHIV, with a focus on survival, toxicity related to chemo- and radio-therapy, and factors associated with better prognosis.
Article PubMed PubMed Central Google Scholar
• Mapanga W, Singh E, Feresu SA, Girdler-Brown B. Treatment of pre- and confirmed cervical cancer in HIV-seropositive women from developing countries: a systematic review. Syst Rev. 2020;9(1):79. https://doi.org/10.1186/s13643-020-01345-2. Interesting systematic review about clinical management of precancerous and cancerous cervical lesions among WLHIV, with a focus on the main problems described in developing Countries.
Article PubMed PubMed Central Google Scholar
• Grover S, Mehta P, Wang Q, Bhatia R, Bvochora-Nsingo M, Davey S, et al. Association between CD4 count and chemoradiation therapy outcomes among cervical cancer patients with HIV. J Acquir Immune Defic Syndr. 2020;85(2):201–8. https://doi.org/10.1097/QAI.0000000000002420. Interesting prospective cohort study from Botswana, whose aim is to determine the effect of nadir and longitudinal CD4+ count changes on ICC survival among WLHIV, after controlling for treatment- and cancer-specific variables.
Article CAS PubMed PubMed Central Google Scholar
Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5(5):CD009069. https://doi.org/10.1002/14651858.CD009069.pub3.
Zizza A, Banchelli F, Guido M, Marotta C, Di Gennaro F, Mazzucco W, et al. Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis. Sci Rep. 2021;11(1):4954. https://doi.org/10.1038/s41598-021-83727-7.
Article CAS PubMed PubMed Central Google Scholar
• Staadegaard L, Ronn MM, Soni N, Bellerose ME, Bloem P, Brisson M, et al. Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: a systematic review and meta-analysis. EClinicalMedicine. 2022;52:101585. https://doi.org/10.1016/j.eclinm.2022.101585. This is a very important meta-analysis of 18 trials which confirms that PLHIV have a robust and safe immune response to all types of HPV vaccines, suggesting that these patients can benefit from receiving HPV vaccination even after HIV infection.
•• Lichter K, Krause D, Xu J, Tsai SHL, Hage C, Weston E, et al. Adjuvant human papillomavirus vaccine to reduce recurrent cervical dysplasia in unvaccinated women: a systematic review and meta-analysis. Obstet Gynecol. 2020;135(5):1070–83. https://doi.org/10.1097/AOG.0000000000003833. Interesting meta-analysis (6 studies included), showing HPV vaccination importance and effectiveness also as a secondary profilaxys after CIN2+ surgical excision, with a reduced risk of recurrent cervical dysplasia overall, referring to the general population (HIV-uninfected women).
• Firnhaber C, Swarts A, Jezile V, Mulongo M, Goeieman B, Williams S, et al. Human papillomavirus vaccination prior to loop electroexcision procedure does not prevent recurrent cervical high-grade squamous intraepithelial lesions in women living with human immunodeficiency virus: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2021;73(7):e2211–6. https://doi.org/10.1093/cid/ciaa1456. Randomized Clinical Trial from South Africa, showing that HPV vaccination after LOOP seems to be uneffective on recurrent HSIL prevention among WLHIV.
Bruni L, Saura-Lazaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021;144:106399. https://doi.org/10.1016/j.ypmed.2020.106399.
Tawe L, MacDuffie E, Narasimhamurthy M, Wang Q, Gaseitsiwe S, Moyo S, et al. Human papillomavirus genotypes in women with invasive cervical cancer with and without human immunodeficiency virus infection in Botswana. Int J Cancer. 2020;146(6):1667–73. https://doi.org/10.1002/ijc.32581.
Article CAS PubMed Google Scholar
Zhang DY, Chen W, Zhang HY, Lv SQ, Lu XN, Tao YP, et al. Cervical neoplastic lesions in relation to CD4 T-lymphocyte counts and antiretroviral therapy among women with clinical stage 1 HIV in Yunnan. China Kaohsiung J Med Sci. 2020;36(6):450–9. https://doi.org/10.1002/kjm2.12175.
Comments (0)